MALDI imaging mass spectrometry: an emerging tool in neurology

被引:28
作者
Schnackenberg, Laura K. [1 ]
Thorn, David A. [1 ]
Barnette, Dustyn [1 ]
Jones, E. Ellen [1 ]
机构
[1] FDA, Natl Ctr Toxicol Res, Div Syst Biol, 3900 NCTR Rd, Jefferson, AR 72079 USA
关键词
MALDI IMS; Spatial distributions; Molecular map; Mass spectrometry; Brain disease; Neurology; Histology; TISSUE LOCALIZATION; NEUROTROPHIC FACTOR; BRAIN; MATRIX; LIPIDS; PEPTIDES; MODEL; QUANTIFICATION; IDENTIFICATION; CELLS;
D O I
10.1007/s11011-021-00797-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Neurological disease and disorders remain a large public health threat. Thus, research to improve early detection and/or develop more effective treatment approaches are necessary. Although there are many common techniques and imaging modalities utilized to study these diseases, existing approaches often require a label which can be costly and time consuming. Matrix-assisted laser desorption ionization (MALDI) imaging mass spectrometry (IMS) is a label-free, innovative and emerging technique that produces 2D ion density maps representing the distribution of an analyte(s) across a tissue section in relation to tissue histopathology. One main advantage of MALDI IMS over other imaging modalities is its ability to determine the spatial distribution of hundreds of analytes within a single imaging run, without the need for a label or any a priori knowledge. Within the field of neurology and disease there have been several impactful studies in which MALDI IMS has been utilized to better understand the cellular pathology of the disease and or severity. Furthermore, MALDI IMS has made it possible to map specific classes of analytes to regions of the brain that otherwise may have been lost using more traditional methods. This review will highlight key studies that demonstrate the potential of this technology to elucidate previously unknown phenomenon in neurological disease.
引用
收藏
页码:105 / 121
页数:17
相关论文
共 84 条
[1]   In situ metabolite and lipid analysis of GluN2D-/- and wild-type mice after ischemic stroke using MALDI MSI [J].
Andrews, William T. ;
Donahue, Deborah ;
Holmes, Adam ;
Balsara, Rashna ;
Castellino, Francis J. ;
Hummon, Amanda B. .
ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2020, 412 (24) :6275-6285
[2]  
Angel PM, 2018, METHODS MOL BIOL, V1788, P225, DOI 10.1007/7651_2017_81
[3]  
Angel Peggi M, 2016, J Heart Valve Dis, V25, P240
[4]  
[Anonymous], 2019, SURVEILLANCE REPORT
[5]   Systemic delivery of P42 peptide: a new weapon to fight Huntington's disease [J].
Arribat, Yoan ;
Talmat-Amar, Yasmina ;
Paucard, Alexia ;
Lesport, Pierre ;
Bonneaud, Nathalie ;
Bauer, Caroline ;
Bec, Nicole ;
Parmentier, Marie-Laure ;
Benigno, Lorraine ;
Larroque, Christian ;
Maurel, Patrick ;
Maschat, Florence .
ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2014, 2
[6]  
Balluff B, 2018, METHODS MOL BIOL, V1730, P345, DOI 10.1007/978-1-4939-7592-1_26
[7]   Quantification and assessment of detection capability in imaging mass spectrometry using a revised mimetic tissue model [J].
Barrymgr, Jeremy A. ;
Groseclose, Mark Reid ;
Castellino, Stephen .
BIOANALYSIS, 2019, 11 (11) :1099-1116
[8]   MALDI Imaging of Lipid Biochemistry in Tissues by Mass Spectrometry [J].
Berry, Karin A. Zemski ;
Hankin, Joseph A. ;
Barkley, Robert M. ;
Spraggins, Jeffrey M. ;
Caprioli, Richard M. ;
Murphy, Robert C. .
CHEMICAL REVIEWS, 2011, 111 (10) :6491-6512
[9]  
Besser M, 1999, J IMMUNOL, V162, P6303
[10]   Region-specific bioconversion of dynorphin neuropeptide detected by in situ histochemistry and MALDI imaging mass spectrometry [J].
Bivehed, Erik ;
Stromvall, Robert ;
Bergquist, Jonas ;
Bakalkin, Georgy ;
Andersson, Malin .
PEPTIDES, 2017, 87 :20-27